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Abstract
EGFR-MEK-ERK signaling pathway has an established role in promoting malignant growth and disease progression in
human cancers. Therefore identification of transcriptional targets mediating the oncogenic effects of the EGFR-MEK-ERK
pathway would be highly relevant. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently characterized human
oncoprotein. CIP2A promotes malignant cell growth and is over expressed at high frequency (40–80%) in most of the
human cancer types. However, the mechanisms inducing its expression in cancer still remain largely unexplored. Here we
present systematic analysis of contribution of potential gene regulatory mechanisms for high CIP2A expression in cancer.
Our data shows that evolutionary conserved CpG islands at the proximal CIP2A promoter are not methylated both in normal
and cancer cells. Furthermore, sequencing of the active CIP2A promoter region from altogether seven normal and
malignant cell types did not reveal any sequence alterations that would increase CIP2A expression specifically in cancer
cells. However, treatment of cancer cells with various signaling pathway inhibitors revealed that CIP2A mRNA expression
was sensitive to inhibition of EGFR activity as well as inhibition or activation of MEK-ERK pathway. Moreover, MEK1/2-specific
siRNAs decreased CIP2A protein expression. Series of CIP2A promoter-luciferase constructs were created to identify
proximal 227 to 2107 promoter region responsible for MEK-dependent stimulation of CIP2A expression. Additional
mutagenesis and chromatin immunoprecipitation experiments revealed ETS1 as the transcription factor mediating
stimulation of CIP2A expression through EGFR-MEK pathway. Thus, ETS1 is probably mediating high CIP2A expression in
human cancers with increased EGFR-MEK1/2-ERK pathway activity. These results also suggest that in addition to its
established role in invasion and angiogenesis, ETS1 may support malignant cellular growth via regulation of CIP2A
expression and protein phosphatase 2A inhibition.
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Introduction
Accumulation of various genetic alterations has been considered
as a prerequisite for cancer development. These genetic alterations
often results in overexpression or activity of proto-oncogenes and
inhibition of the function of tumor suppressor [1,2]. Therefore,
understanding of the mechanisms by which the activity of both
proto-oncogenes and tumor suppressors is altered in cancer is
crucially important both academically, and for development of
new approaches to target cancer cells for therapy.
Epidermal growth factor receptor (EGFR)-mediated MEK1/2-
ERK MAPK pathway activity has been shown to regulate virtually
all aspects involved in tumourigenesis. Accordingly, increased
activity and overexpression of both EGFR and the MEK1/2
kinases has been observed in various human cancers [3,4,5,6].
Moreover, inhibitors for EGFR, Raf and MEK1/2 kinases are in
clinical trials against various types of solid tumors [3,4,7,8].
Interestingly, increased MEK1/2 pathway activity due to
hyperactivity of Ras and Raf proteins has also shown to contribute
to clinical resistance to EGFR tyrosine kinase inhibitor [4,9,10].
These results together suggest that inhibition of the pathway
activity both at the level of the receptor, and its downstream
effectors may be required for an effective anti-cancer therapy.
ETS family of transcription factors including Elk1, ETS1 and
ETS2 are some of the well-known targets for the EGFR-Ras-
MEK1/2 signaling pathway [11]. ETS1 and ETS2 are both
phosphorylated by Ras signaling [11,12]. ETS1 is a founding
family member of ETS-domain transcription factors. It has been
linked to cancer since its identification as an oncogenic fusion with
the product of c-Myb proto-oncogene in the E26 avian leukemia
virus [13,14]. ETS1 is known to target a wide variety of genes
[11,12,15], which in turn dictates its role in various cellular
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17979processes. Pertaining to cancer ETS1 is best known for its role in
promoting tumor cell invasiveness, motility and metastasis [13,16].
Invasion promoting role of ETS1 is thought to be mediated by
transcriptional up regulation of genes that participate on
degradation of extracellular matrix and stimulation of angiogenesis
[16]. Interestingly, even though ETS1 and other ETS-family
transcription factors have been mainly linked to tumor invasion,
soon after cloning of human ETS1, Seth and collaborators
demonstrated that ETS1 overexpression transformed NIH3T3
cells making them capable of anchorage-independent growth and
tumor growth in nude mice [17]. More recently it was also shown
that ETS1 promoted transformed cellular phenotype in human
cells as well [18,19]. However, the target genes involved in the
ETS1-mediated cellular transformation are poorly understood.
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is a
recently characterized human oncoprotein [20]. CIP2A interacts
with and inhibits protein phosphatase 2A (PP2A) tumor suppressor
complex and thereby inhibits dephosphorylation and subsequent
proteolytic degradation of MYC transcription factor [20,21].
CIP2A promotes Ras-elicited foci formation in mouse embryo
fibroblasts and supports transformation of immortalized human
cells [20]. In loss of function studies, CIP2A depletion has been
shown to reduce the overall tumor xenograft size in nude mice
[20,22], and to impair clonogenicity and anchorage-independent
growth of tumor cells [20,22,23,24,25]. Recently, CIP2A was also
shown to inhibit Akt kinase-associated PP2A activity and by these
means to protect human hepatocellular carcinoma cells from
bortezomib-induced apoptosis [26]. CIP2A is expressed in only
very few normal tissues but it is overexpressed with very high
incidence (40–80%) in various human cancer types such as head
and neck squamous cell carcinomas (HNSCC), colon carcinomas,
gastric carcinomas, breast carcinomas and non-small cell lung
cancer [20,22,23,24,25]. In addition to its overexpression in
cancers, recent studies have shown that CIP2A immunopositivity
correlates with aggressive disease and/or poor patient survival in
several cancer types [22,23,24]. With respect to mechanisms
regulating CIP2A expression, we have hitherto identified MYC as
a stimulator of CIP2A expression [24]. However, other mecha-
nisms contributing towards increased CIP2A expression in human
cancers still remain elusive.
In the current study, we cloned functional CIP2A promoter
region and identified the promoter regions mediating high CIP2A
transcriptional activity. In addition, using chemical inhibitors for
various signaling pathways and target specific siRNAs, we
dissected the role of EGFR-MEK1/2 pathway in regulating
CIP2A expression. Chromatin immunoprecipitation, promoter
mutagenesis and target specific siRNAs were then utilized to
identify ETS1 as the transcription factor regulating EGFR-
MEK1/2-dependent CIP2A expression in human cancers.
Results
Bioinformatic analysis and methylation status of CIP2A
Promoter
To initiate a systematic analysis of the mechanisms regulating
CIP2A expression, 1.8 kb sequence upstream of the predicted
CIP2A gene transcription start site was analyzed by using the
Genomatix software. Figure 1A shows the predicted transcription
factor binding sites, having matrix similarity of 95% and core
similarity of 100%, on that genomic region. Genomatix software
wasalsoused toobtainthe phylogenetictreeoftheCIP2A promoter
in different species (Fig. 1B). Interestingly, analysis of the 21500 to
+450 bp region with MethPrimer software identified a CpG island
between nucleotides 2150 to +400 bp (blue shaded region in the
Figure 1C). Importantly, alignment of the CIP2A promoters in
different species also revealed conservation of CpG rich sequences
on that region(Fig. S1A). Methylationof CpG sites intheregulatory
regions of the genes is suggested to correlate with transcriptional
silencing. Therefore, it was hypothesized that CIP2A expression in
normal tissues and cell lines [20,22,23,25] could be silenced due to
promoter methylation. To this end, methylation status of 2150 to
+400 bp region was analyzed by using bisulphite sequencing.
Genomic DNA samples collected for this analysis included freshly
isolated cells from normal human blood, cultured human skin
fibroblasts and cultured cancer cells (AGS and HeLa). Bisulphite
treatment of the genomic DNA resulted in conversion of all
cytosines in the sequenced promoter region to thymidines, in all
samples (Fig. 1D and Fig. S1). Therefore, since methylation of CpG
islands at CIP2A promoter was not observed in normal cells, it is
unlikely that promoter de-methylation would explain increased
CIP2A expression in cancerous cells.
Functional and SNP analysis of CIP2A promoter
Single nucleotide polymorphisms (SNPs) have been reported to
create novel transcription factor binding sites on the gene
promoters. Specifically, a previous study showed that a SNP on
MMP-1 promoter created a novel ETS binding site that
augmented the MMP-1 transcription in cancer cells [27]. In
order to assess the SNP status of CIP2A promoter, a region
containing the CIP2A promoter depicted in Fig. 1A and exon 1
(21802 bp to +182 bp) was sequenced from genomic DNA
extracted from normal human peripheral blood, human non-
malignant mononuclear monocytes (MN-50), normal human
dermal fibroblasts (NHDFc), human fibrosarcoma cell line
(HT1080), squamous cell carcinoma cell line (SCC7), cervical
carcinoma cell line (HeLa) and gastric adenocarcinoma cell line
(AGS). This analysis identified several SNPs on the analyzed
region but only two of them (T.Ca t2592 in HeLa and G.Aa t
21100 in SCC7) were not found from any normal samples
(Fig. 2A). However, as each of these two SNPs were found only
from one cancer cell line, but not in the others analyzed, it is
unlikely that they would create transcription factor binding sites
that would augment CIP2A transcription generally in cancer. Of
note, T.Ca t2592 in HeLa cells has not been previously
documented in the databases.
In order to initiate functional characterization of CIP2A
promoter, the 21802 bp to +182 bp 59 upstream region of
CIP2A gene that was analyzed for SNPs above, was cloned into
pGL4.10 vector to create CIP2A promoter luciferase reporter
construct (21802CIP2ALuc). The promoter region was amplified
from the genomic DNA of AGS cells, and this particular clone
harboured nucleotides A at position 298 and T at the position
21487 (Fig. 2A). In order to estimate the relative transcriptional
activity of the cloned CIP2A promoter fragment, we compared the
luciferase activity of 21802CIP2ALuc to promoter/luciferase
constructs known to be active in cancer cells. As shown in Fig. 2B,
21802CIP2ALuc activity was either equivalent or clearly higher
than activity of EGFRLuc [28] or minimal 5xJunLuc [29]
promoters respectively. Based on this result we concluded that
the cloned 21802 bp to +182 bp 59 upstream region of CIP2A
gene contains an active CIP2A promoter.
Next the 21802CIP2ALuc construct was utilized to analyze
whether the SNPs 592 T.C and 1100G.A identified above were
functional. To this end, 592 T.C and 1100G.A mutations were
introduced to 21802CIP2ALuc by site-specific mutagenesis and
the activity of mutant constructs was compared to wild type
1802CIP2ALuc in AGS cells. On comparison to the wild type,
there was no change seen in CIP2A luciferase activity with the
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marked decrease in the luciferase activity (Fig. 2C).
Finally, in order to characterize the regions at the CIP2A
promoter that mediate its high transcriptional activity, several 59-
deletions of the promoter/reporter were cloned. Comparison of the
basalactivitiesofthesedeletion constructsinAGScellsrevealedthat
regions between 2392 and 21802 did not seem to contain
transcription factor binding sites that would greatly contribute to
high basal activity of CIP2A promoter (Fig. 2D). Interestingly, the
high luciferase activity of 2392CIP2ALuc was significantly reduced
when additional 57 nucleotides were deleted resulting in 2335CI-
P2ALuc construct (Fig. 2D). This seemed to be caused by exposure
of a transcriptional repression domain, as further deletion of
2335CIP2ALuc to 2108CIP2ALuc resulted again in significantly
increased luciferase activity (Fig. 2D). Intriguingly, this 108 bp
CIP2A promoter accounted for more than 50% of the luciferase
activity produced by the 21802CIP2ALuc (Fig. 2D).
Taken together, this data presents first functional analysis of
CIP2A promoter region. Furthermore, these results strongly
suggest that SNPs on CIP2A promoter do not significantly
contribute to CIP2A overexpression in cancer.
Regulation of CIP2A expression by the EGFR-MEK1/2
pathway
Results above suggested that CIP2A expression may be
positively regulated by signaling pathways which stimulate its
Figure 1. Bioinformatic analysis and methylation status of CIP2A Promoter. A. Identification of transcription factor binding sites with matrix
similarity of 95% and core similarity of 100% on 21802 bp CIP2A promoter using Genomatix software. B. Phylogenetic tree depicting the
evolutionary conservation of CIP2A promoter. C. Identification of putative CpG Island from 2150 bp to +400 bp (blue shaded area) on the CIP2A
promoter using MethPrimer software. D. Shows the sequencing results of the extracted genomic DNA from normal human blood. All CpG sites
(represented by black rectangular blocks) lying within the CpG island were converted from CG to TG when treated with bisulphite, thereby implying
that CIP2A promoter at these sites is unmethylated.
doi:10.1371/journal.pone.0017979.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17979Figure 2. Functional and SNP analysis of CIP2A promoter. A. Identified single nucleotide polymorphisms on 21802 to +182 region of CIP2A
promoter from indicated cells. Two cancer cell line specific changes were observed, namely G/A at 21101 in SCC-7 cell line and T/C at 2592 in HeLa
cell line. B. Relative Luciferase assay showing the relative activity of 21802 bp of CIP2A promoter in comparison to well known oncogenic promoters
like EGFRLuc and 5xJunLuc. C. Luciferase assay showing comparison of activity between wild type (WT) CIP2A promoter and the indicated SNP
mutants. D. Luciferase assay showing the activity of indicated CIP2A promoters. High basal activity is mediated by first 392 bp of the promoter, out of
which, almost two-thirds of it was due to the first 108 bp. B–D, Shown is the Mean+SD from three independent experiments.
doi:10.1371/journal.pone.0017979.g002
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17979Figure 3. Regulation of CIP2A expression by the EGFR-MEK1/2 pathway. A. Quantitative PCR (qPCR) analysis showing levels of CIP2A mRNA
extracted from AGS cells treated with DMSO, SB23580 (20 uM), LY294002 (10 uM), PD98059 (20 uM), AG1478 (10 uM) and TPA (100 nM) at 24 h time
point. While a decrease in CIP2A mRNA level was observed with PD98059 and AG1478 treatments, TPA treatment augmented the CIP2A mRNA levels
in AGS cells. B. qPCR analysis showing time-dependent regulation of CIP2A mRNA levels in AGS cells treated with DMSO, AG1478 (10 uM) and TPA
(100 nM) for indicated time points. C and D Luciferase assays showing the activity of indicated CIP2A promoter deletions in cells treated either with
DMSO, AG1478 (10 uM) or TPA (100 nM) for 24 h. (*, P,0.05; n.s.=non-significant). B–D. Shown is the Mean+SD from three independent
experiments.
doi:10.1371/journal.pone.0017979.g003
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signaling pathways had role in regulating CIP2A expression,
AGS cells were treated with well-defined chemical pathway
inhibitors and activators. While inhibition of either p38 or PI3
kinases by SB23580 or LY294002, respectively, did not regulate
in CIP2A mRNA levels, both MEK1/2 and EGFR inhibitors
(PD98059 and AG1478) decreased CIP2A mRNA expression
(Fig. 3A). Moreover, treatment of cells with phorbol ester TPA,
a well-characterized activator of MEK1/2-ERK signaling
pathway, increased CIP2A mRNA expression more than
threefold (Fig. 3A). As shown in Fig. 3B, the effects of both
AG1478 and TPA on CIP2A mRNA expression were already
e v i d e n t6h o u r sp o s tt r e a t m e n tw h i c hs u g g e s t sad i r e c tm o d eo f
action. In order to map the region on CIP2A promoter that is
responsive to the EGFR-MEK1/2 pathway activity, cells
transfected with various length of CIP2A luciferase promoter
constructs were treated with AG1478 or TPA, and luciferase
activity, as compared to control DMSO treatment, was
measured as a read-out of promoter activity. As shown in
Figs. 3C and D, AG1478 treatment decreased, while TPA
treatment increased the luciferase activity from all except the
shortest 227CIP2ALuc construct.
Taken together, these results show that CIP2A expression is
positively regulated‘ by EGFR-MEK1/2 pathway and that the
region responsive for the pathway activity lies between 227 bp
and 2672 bp on the CIP2A promoter.
Characterization of MEK1/2 kinase responsive region on
the CIP2A promoter
In order to validate the contribution of MEK1/2 kinases in the
positive regulation of CIP2A expression, AGS cells were treated
with UO126, a more specific and potent MEK1/2 inhibitor than
the previously used PD98059, and CIP2A protein expression was
studied 48 hours post treatment. As shown in Fig. 4A, UO126
dose-dependently decreased CIP2A protein expression. Further-
more, two different siRNAs against both MEK1 and MEK2
decreased CIP2A protein expression in AGS cells (Fig. 4B).
Importantly the effects were not cell line specific as either
chemical or siRNA-based MEK1/2 inhibition inhibited CIP2A
protein expression also in PC-3 prostate cancer cell line (Fig. S2).
To narrow down the MEK1/2-responsive region on the CIP2A
promoter, AGS cells transfected with series of CIP2A luciferase
reporter constructs were treated with UO126 (20 uM) and
luciferase activities were measured 48 h post-treatment. In line
with the results seen with AG1478 and TPA treatments,
decreased luciferase activity of all of the other constructs except
the 227CIP2ALuc was observed in UO126 treated cells (Fig. 5A).
To further narrow down the MEK1/2-responsive region on the
CIP2A promoter, various additional CIP2A luciferase promoter
constructs were cloned (Fig. 5B). Comparison of the basal
activities of these new constructs together with selected promoter
constructs already analyzed in Fig. 2D, further confirmed that
there are both repressive an activating promoter regions at
CIP2A promoter between 227 bp and 2400 bp (Fig. 5B).
However, regardless of the basal activity of the reporter, UO126
treatment inhibited the activity of all reporters, including
2108CIP2ALuc, with a notable exception of the 227CIP2ALuc
construct (Fig. 5C). Therefore, these results demonstrate that
MEK1/2 kinases positively regulate both CIP2A promoter
activity and protein expression. Moreover, these results identify
81 bp between 2108 bp and 227 as a MEK1/2-responsive
region on CIP2A promoter.
EGFR-MEK1/2 pathway regulates CIP2A expression
through ETS1
In order to identify the transcription factor(s) mediating the
stimulatory effects of EGFR-MEK1/2 pathway in regulating
CIP2A expression, we reverted back to the bioinformatic analysis
done for the region between 227 bp to 2108 bp (Fig. 1A). Out of
the transcription factors predicted to bind to that region, ETS1 has
an established role as a downstream effector of the MEK1/2
pathway [11,12]. Therefore, we next created mutants for these
ETS1 sites and compared the luciferase activity of the 2108CI-
P2ALuc constructs harboring the mutations to that of the wild
type. The two ETS sites and the mutation strategy are depicted in
Fig. 6A, B. As shown in Fig. 6C, mutation of either of the ETS1
sites dramatically decreased the CIP2A promoter activity. To
investigate whether ETS1 mediates the MEK1/2-dependent
CIP2A regulation, cells transfected with both wild type and
ETS1 mutant (site 1) 2108CIP2ALuc constructs were treated
either with AG1478, UO126 or TPA. While the wild type
2108CIP2ALuc activity was significantly inhibited by AG1478
(Fig. 6D) or UO126 (Fig. 6E), and conversely activated by TPA
(Fig. 6F), the ETS1 mutant promoter did not significantly respond
to these treatments.
Figure 4. MEK1/2 kinases positively regulate CIP2A protein
expression in human cancer cells. A. Western blot showing
concentration dependent effect of specific MEK inhibitor, U0126, on
CIP2A protein levels in AGS cells at 48 h time point. B. Western blot
showing the effect of both MEK1 and MEK2 siRNAs on CIP2A protein
levels in AGS cells at 72 h time point.
doi:10.1371/journal.pone.0017979.g004
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on the proximal CIP2A promoter. Moreover, these results strongly
suggest that the MEK1/2-dependent stimulation of CIP2A
promoter activity is mediated by ETS-family transcription factors.
ETS1 binds to CIP2A promoter and regulates its
expression in cancer cells
To verify that ETS proteins do bind to the CIP2A promoter on
MEK1/2 activity-dependent manner, we performed chromatin
immunoprecipitation experiment with ETS1 antibody and ampli-
fication of the 266 bp to +20 bp fragment of the CIP2A promoter.
As shown in Fig. 7A, ETS1 immunoprecipitation resulted in about
4-fold enrichment of CIP2A promoter occupancy as compared to
the control IgG. Interestingly, in the same experiment CIP2A
enrichment was even stronger than UNQ9419, an established
ETS1 target that was used as a positive control [30]. Moreover,
enrichment of CIP2A promoter was significantly inhibited by
treatment of cells with U0126. Additionally, while the inhibition of
CIP2A enrichment by UO126 was statistically significant, the
inhibition of UNQ9419 enrichment was not (Fig. 7A).
Results above demonstrated that ETS elements mediate largely
the basal and MEK-elicited activity of minimal 2108CIP2ALuc
promoter (Fig. 6). In order to establish whether these ETS
elements are essential for full-length CIP2A promoter activity we
mutated these sites on 21802CIP2ALuc and compared its activity
to that of the wild type. As shown in Fig. 7B, mutation of either of
the ETS1 sites dramatically decreased the 21802CIP2ALuc
promoter activity. Additionally, in order to verify that ETS1
regulates endogenous CIP2A protein expression, two different
siRNAs specific for ETS1 were transfected in AGS cells and cell
lysates were immunoblotted 48 hours after for CIP2A, ETS1 and
Actin levels. As shown in Fig. 7C, decreased CIP2A protein levels
were observed with both of the ETS1 specific siRNAs. In addition,
ETS1 positively regulated CIP2A expression in PC-3 (Fig. 7D) and
LNCaP prostate cancer cell lines (Fig. 7E). Together, these results
provide concrete experimental evidence of ETS1 being the
transcription factor mediating EGFR-MEK1/2 dependent regu-
lation of CIP2A in cancer cells.
Finally, in order to reveal whether the expression status of
EGFR-MEK-ETS1 pathway components and CIP2A in human
cancers, we referred to the Oncomine database (www.oncomine.
org). This analysis revealed M6 subtype of acute myeloid leukemia
as a cancer type in which CIP2A and representative genes of each
level of the pathway (EGFR, MEK2 and ETS1) were significantly
upregulated in two different genome wide leukemia studies [31,32]
(Fig. 8).
Discussion
A recent systematic characterization of somatic mutations in
441 human tumors identified growth factor receptor signaling to
MEK1/2-ERK pathway to be one of the most significantly
altered pathways across human cancers [33]. Moreover, inhibi-
tion of oncogenic form of B-Raf in human malignant melanomas
by a small-molecule inhibitor demonstrated very promising
clinical efficacy already in phase I clinical trial [7]. Based on
results of these studies and ample of earlier data demonstrating
oncogenic function of EGFR-mediated MEK1/2-ERK pathway
activation, it is evident that identification of oncogenic effectors of
the pathway activity is important. In this study we demonstrate
that CIP2A is a novel oncogenic target upregulated by EGFR-
induced MEK1/2-ERK pathway activity. After its original
cloning [34], and further functional characterization [20], CIP2A
has been demonstrated to promote malignant cell growth by
using various human cancer cell models [20,22,23,24,25].
Moreover, the CIP2A protein has been shown to be overex-
pressed with very high frequency in different types of human
malignancies. Except human breast cancer where CIP2A is
overexpressed in 40% of patient samples [22], in all other studied
cancer types the frequency is between 65 to 87% of patients
[20,23,24,25]. This makes CIP2A overexpression together with
MEK1/2-ERK pathway activation as one of the most frequent
alterations in human cancers. However, prior to this study, the
mechanisms by which CIP2A expression is induced in human
cancer cells have been very poorly understood.
In order to identify mechanisms responsible for high basal
expression of CIP2A in human cancer cells, we have in this study
systematically analyzed contribution of several potential gene
regulatory mechanisms that have been earlier shown to affect
gene expression in human cancers. Although we have not
exclusively ruled out that either promoter methylation or
functional SNPs at the CIP2A promoter might contribute to
high CIP2A expression in cancer, our data does indicate that
these mechanisms most probably are not relevant for regulation
of the CIP2A promoter activity. In order to identify promoter
regions functionally implicated in regulation of CIP2A expression
in cancer cells, we created altogether 10 promoter deletion
reporter constructs. Data shown in figures 2D and 5B allowed us
to conclude that the promoter region between 2335 bp and
2392 bp contains a strong activating promoter element, whereas
region between 2108 bp and 2204 bp contains a strong
repressor element. Furthermore, the data shows, that promoter
region upstream of 2417 bp do not significantly contribute to the
high basal activity of the studied CIP2A promoter in AGS cells,
whereas, promoter region between 227 bp and 2108 bp has a
very strong activating element accounting for at least 50% of the
total activity of the 21802 bp promoter. In addition to promoter
regulation, another important mechanism that contributes
towards protein expression is modification of its turn over rate
or stability. CIP2A has been previously shown to be very long
lived protein in hepatocellular carcinoma cell line [26].
Therefore, elucidation of mechanisms contributing towards
CIP2A stability in cancer cells will be a relevant question to be
addressed in the future.
Our subsequent experiments with the CIP2A promoter
identified two partly overlapping ETS-binding sites between
260 bp to 230 bp to be largely responsible for high activity of
the full-length promoter. Interestingly, it’s been shown that over
two-thirds of the 27 genes of the human ETS family can be co-
expressed in a given cell type [35]. Moreover, in principle all ETS
proteins can recognize the same 59-GGA(A/T)-39 motif within a
particular promoter [35]. This extensive co-expression and
Figure 5. Characterization of MEK kinase responsive region on the CIP2A promoter. A. Luciferase assay showing the activity of different
length CIP2A promoters when treated with DMSO and U0126 (10 uM) for 24 h, identifying the MEK responsive region to lie between 2672 bp to
227 bp of the CIP2A promoter. B. Luciferase assay showing the basal activity indicated CIP2A promoters. C. Luciferase assays showing the activity of
different length CIP2A promoters when treated with DMSO and U0126 (10 uM) for 24 h, further narrowing down the MEK responsive region to be
between 2108 bp and 227 bp of the CIP2A promoter (*, P,0.05; **, P,0.00; n.s.=non-significant). Shown is the Mean+SD from three independent
experiments.
doi:10.1371/journal.pone.0017979.g005
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PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17979Figure 6. EGFR-MEK pathway regulates CIP2A expression through ETS-1. A. Schematic diagram of the 108 bp fragment of CIP2A promoter
showing the location of two overlapping predicted ETS1 binding sites. B. Sequencing results of ETS-1 binding site mutants on the CIP2A promoter
created using mutagenesis. The sequence on the top represents the wild type sequence (read from 59 to 39 end), while the sequence below is the
mutated sequence (read from 59 to 39 end). The induced change in the sequence is shown within the rectangular box. C. Luciferase assay comparing
the activity of either wild type 2108CIP2ALuc or indicated ETS binding site mutant 2108CIP2ALuc constructs. D,E&F. Luciferase assays comparing the
activity of either wild type 2108CIP2ALuc or ETS1 Site1 mutant 2108CIP2ALuc constructs after treatment with DMSO, AG1478 (10 uM; D), UO126
(10 uM; E) or TPA (100 nM; F) for 24 h. (*, P,0.05; **, P,0.01; n.s.=non-significant). Shown is the Mean+SD from three independent experiments.
doi:10.1371/journal.pone.0017979.g006
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particular ETS protein to a specific promoter a challenge.
However, results of our siRNA experiments in three different
cancer cell lines show positive regulation of CIP2A expression by
ETS1 (Fig. 7C,D,E). Moreover, our chromatin immunoprecip-
itation experiments, using an ETS1 specific antibody, revealed a
4 fold enrichment of CIP2A promoter occupancy (Fig. 7A). In
addition, the results of a recent study [36], demonstrating binding
of ETS1 on CIP2A promoter in Jurkat T-cell leukemia strongly
supports our main conclusion that ETS1 specifically is involved in
positive regulation of CIP2A. However, due to the cell type
specificity and co-operative DNA binding between the ETS
family members, possibility of other ETS family members also
regulating CIP2A expression cannot be ruled out. Therefore, it is
evident that further analysis of the functional relevance of the
other predicted transcription factor binding sites, and other ETS
family members, in CIP2A regulation (Fig. 1A), will be an
important future research goal.
Many earlier studies have shown that ETS1 promotes, in
addition to invasion related processes [16], also cellular transfor-
mation [17,18,19]. Regardless of this, the ETS1 target genes
supporting cellular transformation are poorly identified. In this
study, we validate CIP2A as a novel ETS1 target gene. As
described above, CIP2A has been shown to promote proliferation
and anchorage independent growth of various cancer cell lines and
siRNA-mediated CIP2A depletion has been shown to very
potently inhibit xenograft tumor growth [20,22]. Moreover,
overexpression of CIP2A promotes human cell transformation
Figure 7. ETS-1 binds to CIP2A promoter and regulates its expression in cancer cells. A. Chromatin immunoprecipitation assay of ETS1
binding to CIP2A promoter in either DMSO or UO126 treated cells. UNQ9419 promoter is shown as a positive control. (*, P,0.05; **, P,0.01;
n.s.=non-significant). B. Luciferase assay comparing the activity of either wild type 21802CIP2ALuc or indicated ETS binding site mutant
21802CIP2ALuc constructs. C,D&E. Western blot analysis of CIP2A and ETS1 protein levels in either AGS (C), PC-3 (D) or LNCaP (E) cells transfected
with scrambled (Scr.) or ETS-1 specific siRNAs for 72 h.
doi:10.1371/journal.pone.0017979.g007
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knockdown does not affect cancer cell migration or invasion
through matrigel [20,23]. Taken together, these results may allow
us to speculate that positive regulation of CIP2A contributes to the
less explored ETS1 driven processes such as capacity to grow in an
anchorage independent manner and cellular transformation. Both
ETS1 and CIP2A have been associated with clinical aggressivity in
breast cancer [22,37]. Our own bioinformatics analysis of
overexpression of CIP2A and components of EGFR-MEK1/2-
ETS1 pathway revealed M6 subtype of acute myeloid leukemia
(AML) as a cancer type in which CIP2A and representative genes
of each level of the pathway are significantly up regulated (Fig. 8)
[31,32]. Importantly, CIP2A overexpression in AML patients
compared to healthy controls was recently verified both at mRNA
and protein level [38].
In summary, this work provides first systematic analysis of
mechanisms regulating expression of a newly characterized human
oncoprotein CIP2A. Our results demonstrate that EGFR-MEK1/
2-ETS1 pathway is a critical positive regulator of CIP2A
expression. Thereby these results reveal a potential link between
deregulated EGFR-MEK1/2-ETS1 pathway signaling and
CIP2A-dependent tumor growth. Importantly, in addition to its
scientific impact, this work also provides several important
resources for future studies aiming at characterizing mechanisms
that regulate CIP2A expression both in pathological as well as
physiological situations.
Materials and Methods
Plasmid constructs
The upstream region of the CIP2A promoter containing exon 1
(21802 bp to +182 bp) was amplified by PCR from the genomic
DNA of AGS cells, and the fragment was cloned into pGL4.10-
Basic vector (Promega, Madison, WI, U.S.A) between XhoI and
Bgl II restriction enzyme sites. Then various length luciferase
promoter constructs were created using the Deletion Kit for Kilo-
Sequencing (Takara Bio Inc., Japan) as per the manufacturer’s
instructions. All constructs were sequenced before use.
Transient transfections of plasmids and luciferase assay
All cell lines were obtained from ATCC. AGS cells were plated
in each well of the 96-well plate on day one. Next day respective
luciferase reporter construct was transfected using Fugene (Roche
Diagnostics, IN, U.S.A) according to the manufacturer’s direc-
tions. To normalize the luciferase activity, a control plasmid
expressing Renilla luciferase sequence was co-transfected into the
cells. Cells were then analysed 48 h post-transfection using the
Dual – Glo Luciferase Assay System (Promega, Madison, WI,
Figure 8. Bioinformatic analysis of CIP2A, MEK2, ETS1 and EGFR expression in acute myeloid leukemias. A,B,C&D. Oncomine database
analysis of gene expression profiles for EGFR-MEK-ETS1 pathway genes revealed M6 subtype of acute myeloid leukemia as a cancer type in which
CIP2A and representative genes of each level of the pathway are significantly upregulated (**,P,0.01).
doi:10.1371/journal.pone.0017979.g008
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luciferase levels. EGFRLuc (region 21109 to 216) was a kind gift
by Dr. Micheal Birrer, and 5xJunLuc containing jun2 element
from the c-jun promoter in front of the thymidine kinase promoter
(TK) was a kind gift by Dr. Hans Van Dam [29].
DNA Extraction and Bisulphite sequencing
Genomic DNA of the cell lines and blood sample was extracted
using DNA isolation kit (Nucleon
TM BACC Genomic DNA
Extraction Kit, GE Healthcare Europe GmbH). Bisulfite modifi-
cation of genomic DNA was carried out by using EZ DNA
methylation kit (Zymo Research, Orange, CA) according to the
manufacturer’s instructions. Primers are described in Table S1.
qRT-PCR
mRNA was extracted from cells by using RNeasy kit (Qiagen,
Valencia, CA) and converted to cDNA by using M-MLV Reverse
Transcriptase kit (Promega, Madison, WI, U.S.A.). cDNAs were
subjected to quantitative real-time PCR by using Light Cycler
(Roche Diagnostics, IN, U.S.A.) and SYBR Green PCR Master
Mix kit (Roche Diagnostics, IN, U.S.A) as described previously
[24]. Primers are described in Table S1.
Mutagenesis
Mutagenesis for CIP2A promoter constructs was done using
QuickChange site directed mutagenesis kit from Stratagene (La
Jolla, CA, USA). Primers are described in Table S1. Mutations
were verified by sequencing and two individual clones for each
mutation was used to verify results.
siRNA experiments
HP Validated siRNAs for human MEK1/2 and ETS1 were
purchased from (Qiagen Technologies). Cells were transfected
with 100 pmoles of siRNA per well in a six-well plate using
Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA) in
antibiotic free growth medium, as per the manufacturer’s
instructions. Cells were harvested, and mRNA was extracted
24 h posttransfection. For Western Blots, cells were harvested and
lysates prepared 72 h posttransfection. siRNA sequences are
described in Table S1.
Chromatin immunoprecipitation
The ChIP procedure was performed as described previously
[39] with AGS cells grown to 70–80% confluence. The chromatin
was sheared to an average size of 200–500 bp. After cross-linking
reversal and proteinase K digestion, each individual IP was
purified with the use of a QIAquick PCR purification kit (Qiagen,
Valencia, CA,USA), and samples were eluted with 50 ml of elution
buffer. After elution the IPs were examined by gene-specific
qPCR. Primers are described in Table S1. The antibodies used
were ETS1 (C20) and control IgG both from Santa Cruz,
Biotechnology, Santa Cruz, CA, USA).
Protein extraction and western blotting
Proteins were extracted in hot Laemmli sample buffer and
subjected to Western blot analysis. 30 mg total protein extracts
were separated by 12% SDS-PAGE and transferred to nitrocel-
lulose membranes. Membranes were blocked with 5% non-fat
milk in TBS-0.1%-NP40 and then incubated with mouse
monoclonal MEK1 (H8), the mouse monoclonal MEK2 (A-1),
the rabbit polyclonal ETS1 (C20), goat polyclonal anti-b-Actin (all
from Santa Cruz, Biotechnology, Santa Cruz, CA, USA) or with
rabbit polyclonal anti-CIP2A [34].
Statistical Analysis
Statistical significance was calculated using two-sided Student t-
test (SPSS Inc.) and included in the respective figure legend.
Supporting Information
Figure S1 Methylation Status of CIP2A Promoter. A.
Diagram shows alignment of CIP2A promoter in various lower
species showing conserved CpG sites (represented by rectangular
boxes) in them. B,C,D&E. Shows the sequencing results of the
extracted genomic DNA from normal human blood (B), normal
human dermal fibroblasts (C), AGS cells (D) and HeLa (E) cell
lines. All CpG sites (represented by black rectangular blocks) lying
within the CpG island were converted from CG to TG when
treated with bisulphite, thereby implying that CIP2A promoter is
not methylated at these sites.
(EPS)
Figure S2 MEK1/2 kinases positively regulate CIP2A
protein expression in human cancer cells. A. Western blot
showing effect of specific MEK inhibitor, U0126, on CIP2A
protein levels in PC-3 cells at 48 h. B&C. Western blot showing
the effect of both MEK1 (A) and MEK2 (B) siRNAs on CIP2A
protein levels in PC-3 cells at 72 h time point. CIP2A expression
was reduced by both MEK siRNAs.
(EPS)
Table S1 Sequences of primers and siRNAs.
(EPS)
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